Erectile-dysfunction therapies

Renaud, R; Xuereb, Hayley

doi:10.1038/nrd898

Cited by 22 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high cost and the long time required to bring drugs into commerce [ 1 – 3 ] is driving efforts to repurpose FDA approved drugs—to find new uses for which they weren’t intended, and to thereby reduce the overall cost of commercialization, and shorten the lag between drug discovery and availability [ 4 ]. Among the successes of this approach are sildenafil, originally developed as a cardiovascular drug [ 5 ] and repositioned to treat erectile dysfunction; and zidovudine (AZT), originally developed as an anticancer drug [ 6 ], and repositioned for the treatment of HIV. These discoveries, though serendipitous, motivated more systematic approaches which might amplify the number of discoveries many-fold.…”

Section: Introductionmentioning

confidence: 99%

A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer

Chen

Sherr

et al. 2016

BMC Med Genomics

View full text Add to dashboard Cite

BackgroundThe high cost and the long time required to bring drugs into commerce is driving efforts to repurpose FDA approved drugs—to find new uses for which they weren’t intended, and to thereby reduce the overall cost of commercialization, and shorten the lag between drug discovery and availability. We report on the development, testing and application of a promising new approach to repositioning.MethodsOur approach is based on mining a human functional linkage network for inversely correlated modules of drug and disease gene targets. The method takes account of multiple information sources, including gene mutation, gene expression, and functional connectivity and proximity of within module genes.ResultsThe method was used to identify candidates for treating breast and prostate cancer. We found that (i) the recall rate for FDA approved drugs for breast (prostate) cancer is 20/20 (10/11), while the rates for drugs in clinical trials were 131/154 and 82/106; (ii) the ROC/AUC performance substantially exceeds that of comparable methods; (iii) preliminary in vitro studies indicate that 5/5 candidates have therapeutic indices superior to that of Doxorubicin in MCF7 and SUM149 cancer cell lines. We briefly discuss the biological plausibility of the candidates at a molecular level in the context of the biological processes that they mediate.ConclusionsOur method appears to offer promise for the identification of multi-targeted drug candidates that can correct aberrant cellular functions. In particular the computational performance exceeded that of other CMap-based methods, and in vitro experiments indicate that 5/5 candidates have therapeutic indices superior to that of Doxorubicin in MCF7 and SUM149 cancer cell lines. The approach has the potential to provide a more efficient drug discovery pipeline.Electronic supplementary materialThe online version of this article (doi:10.1186/s12920-016-0212-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer

Chen

Sherr

et al. 2016

BMC Med Genomics

View full text Add to dashboard Cite

show abstract

“…212b,213 In addition, the high costs and failure rates to bring drugs to market have led to more and more interest in drug r&r. 214 Drug r&r is primarily driven by serendipitous observations in clinical and preclinical in vivo settings, of which the high profile drug sildenafil by Pfizer, first developed for angina but later approved for erectile dysfunction, is an emblematic example. 215 Another classic example is thalidomide by Celgene, first marketed for morning sickness, and then approved for leprosy and recently for multiple myeloma. 216 Genomic screens have also contributed to find new uses for known drugs.…”

Section: Rescuing and Repurposing Drugs For Malariamentioning

confidence: 99%

“Recycling” Classical Drugs for Malaria

et al. 2014

View full text Add to dashboard Cite

“…A famous example was the incidental discovery that sildenafil (Viagra; Pfizer), originally used to relieve the symptoms of angina, was also effective for erectile dysfunction, receiving United States Food and Drug Administration approval in 1998 . Within the first 3 years of approval, nearly 8 million men were taking sildenafil in the US alone, with annual sales of US$1.5 billion . Similarly, thalidomide was first marketed in 1957 as a sedative but withdrawn in 1961 after it caused skeletal defects in more than 15 000 children.…”

Section: Examples Of Successful Drug Repurposingmentioning

confidence: 99%

Drug repurposing in the era of COVID ‐19: a call for leadership and government investment

Martin

2020

Medical Journal of Australia

View full text Add to dashboard Cite

Erectile-dysfunction therapies

Cited by 22 publications

References 3 publications

A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer

A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer

“Recycling” Classical Drugs for Malaria

Drug repurposing in the era of COVID ‐19: a call for leadership and government investment

Contact Info

Product

Resources

About